Zhejiang Ausun Pharmaceutical Co., Ltd. (SHA:603229)
7.52
-0.19 (-2.46%)
Sep 11, 2026, 3:00 PM CST
SHA:603229 Revenue
Zhejiang Ausun Pharmaceutical had revenue of 158.94M CNY in the quarter ending June 30, 2026, a decrease of -9.30%. This brings the company's revenue in the last twelve months to 778.50M, down -0.80% year-over-year. In the year 2025, Zhejiang Ausun Pharmaceutical had annual revenue of 792.76M, down -0.32%.
Revenue (ttm)
778.50M
Revenue Growth
-0.80%
P/S Ratio
7.97
Revenue / Employee
586.22K
Employees
1,328
Market Cap
6.20B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 792.76M | -2.53M | -0.32% |
| Dec 31, 2024 | 795.29M | -21.48M | -2.63% |
| Dec 31, 2023 | 816.77M | 52.22M | 6.83% |
| Dec 31, 2022 | 764.55M | 194.85M | 34.20% |
| Dec 31, 2021 | 569.70M | 160.45M | 39.21% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Star Lake Bioscience Co., Inc.Zhaoqing Guangdong | 15.93B |
| Youcare Pharmaceutical Group | 2.46B |
| Novogene | 2.28B |
| China Resources Boya Bio-pharmaceutical Group Co.,Ltd | 1.69B |
| Chengdu Kanghua Biological Products | 1.22B |
| Bio-Thera Solutions | 1.01B |
| R&G PharmaStudies | 939.31M |
| Wuhan Keqian Biology Co.,Ltd | 836.28M |